Executive Summary
GTX-102 is an investigational antisense oligonucleotide (ASO) therapy developed by GeneTx (acquired by Ultragenyx in 2019) for the treatment of Angelman syndrome, a rare neurodevelopmental disorder caused by loss of maternal UBE3A expression in the brain. Unlike traditional gene therapy approaches that aim to deliver a functional UBE3A gene, GTX-102 takes an innovative approach by targeting the UBE3A-ATS (antisense transcript) that silences the paternal allele, thereby allowing reactivation of the normally silent paternal UBE3A gene.
This Phase 1/2 clinical trial represents a first-in-class approach to treating Angelman syndrome by addressing the underlying epigenetic mechanism rather than directly replacing the missing gene.
Pathway / Mechanism Diagram
graph TD
A["UBE3A Gene (15q11.2)"] --> B["Maternal: Active in Neurons"]
A --> C["Paternal: Silenced by Imprinting"]
D["Maternal UBE3A Loss"] --> E["No Functional UBE3A"]
E --> F["Impaired Ubiquitin-Proteasome"]
F --> G["Substrate Accumulation"]
G --> H["Synaptic Dysfunction"]
H --> I["Impaired LTP"]
I --> J["Intellectual Disability"]
H --> K["E/I Imbalance"]
K --> L["Seizures"]
E --> M["Disrupted CaMKII"]
M --> N["Motor Dysfunction"]
O["Therapy: Paternal UBE3A Unsilencing"] --> P["ASO Targeting UBE3A-ATS"]
P --> Q["Restore UBE3A Expression"]
style D fill:#ef5350,color:#e0e0e0
style Q fill:#1b5e20,color:#e0e0e0
Trial Overview
...Executive Summary
GTX-102 is an investigational antisense oligonucleotide (ASO) therapy developed by GeneTx (acquired by Ultragenyx in 2019) for the treatment of Angelman syndrome, a rare neurodevelopmental disorder caused by loss of maternal UBE3A expression in the brain. Unlike traditional gene therapy approaches that aim to deliver a functional UBE3A gene, GTX-102 takes an innovative approach by targeting the UBE3A-ATS (antisense transcript) that silences the paternal allele, thereby allowing reactivation of the normally silent paternal UBE3A gene.
This Phase 1/2 clinical trial represents a first-in-class approach to treating Angelman syndrome by addressing the underlying epigenetic mechanism rather than directly replacing the missing gene.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Trial Overview
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04259281 |
| Sponsor | GeneTx, LLC (acquired by Ultragenyx Pharmaceutical Inc.) |
| Phase | Phase 1/2 |
| Status | Active, recruiting |
| Start Date | January 2020 |
| Estimated Completion | 2027 |
| Study Type | Interventional |
| Allocation | Randomized (dose escalation) |
| Intervention Model | Sequential Dose Escalation |
Disease Context: Angelman Syndrome
Clinical Presentation
[Angelman syndrome](/diseases/angelman-syndrome) is a rare neurodevelopmental disorder caused by loss of maternal UBE3A expression in the brain. The condition is characterized by:
- Onset: Early childhood (typically 6-12 months)
- Core features: Severe intellectual disability, ataxia (characteristic "happy" gait), minimal to no speech, seizure disorder (affects ~80% of patients)
- Behavioral characteristics: Frequent smiling, laughter, hand-flapping, hyperactivity, short attention span
- Additional features: Sleep disorders, feeding difficulties, microcephaly, scoliosis
- Prognosis: Lifelong condition with significant care needs; life expectancy generally normal
Epidemiology
- Prevalence: 1 in 10,000-20,000 individuals
- Gender distribution: Equal between males and females (though genomic imprinting effects differ by sex)
- Inheritance: Usually sporadic (not inherited); various genetic mechanisms
Causes and Genetics
Angelman syndrome results from loss of maternal UBE3A expression in the brain. The underlying mechanisms include:
| Mechanism | Frequency | Description |
|-----------|-----------|-------------|
| Maternal deletion | 70% | Deletion of 15q11-q13 region on maternal chromosome |
| Paternal uniparental disomy | 5-10% | Both copies of chromosome 15 from father |
| Imprinting center defect | 3-5% | Epigenetic silencing of maternal allele |
| UBE3A mutation | 10-20% | Point mutations in maternal UBE3A gene |
UBE3A Biology and Imprinting
The UBE3A gene undergoes genomic imprinting—a process where gene expression is determined by whether the gene is inherited from the mother or father:
Maternal allele: Active in neurons (expressed)
Paternal allele: Silenced by UBE3A-ATS transcript in neuronsThis creates a unique therapeutic opportunity: if the paternal allele could be reactivated, it might compensate for the lost maternal allele. GTX-102 targets this mechanism by reducing UBE3A-ATS expression.
Study Design
Population Characteristics
| Characteristic | Criteria |
|---------------|----------|
| Age | 4-17 years |
| Diagnosis | Genetically confirmed Angelman syndrome (maternal deletion, UBE3A mutation, or imprinting defect) |
| Cognitive requirement | Bayley-III cognitive score ≤55 |
| Seizure requirement | Stable anti-seizure medication for ≥4 weeks |
| Exclusion | Active severe medical conditions, prior ASO treatment |
Treatment Protocol
- Drug: GTX-102 (antisense oligonucleotide)
- Route: Intravenous infusion
- Dosing schedule:
- Loading phase: Every 4 weeks for 12 weeks (3 doses)
- Maintenance phase: Every 8 weeks thereafter
- Dose escalation: Multiple dose levels evaluated
Dose Escalation Scheme
| Cohort | Dose | Status | Participants |
|--------|------|--------|--------------|
| 1 | 2 mg/kg | Completed | 6 |
| 2 | 4 mg/kg | Completed | 6 |
| 3 | 6 mg/kg | Completed | 6 |
| 4 | 10 mg/kg | Recruiting | 6 |
Primary Endpoints
Safety and tolerability — Incidence and severity of adverse events
Pharmacokinetics — Plasma concentration-time profile
Incidence of treatment-emergent adverse events (TEAEs)
Immunogenicity — Anti-drug antibody formationSecondary Endpoints
Cognitive function — Bayley-III Cognitive Composite Score
EEG normalization — Change in background EEG abnormalities
Behavioral outcomes — ABC-C (Aberrant Behavior Checklist-Community)
Communication — Expressive and receptive language measures
Motor function — Gross motor development
Expression biomarkers — UBE3A expression in skin biopsy (fibroblasts)Mechanism of Action
Antisense Oligonucleotide Technology
GTX-102 is a gapmer-style antisense oligonucleotide designed to bind to the UBE3A-ATS (antisense) transcript and promote RNase H-mediated degradation.
How ASOs Work
Binding: The ASO binds to complementary RNA sequence via Watson-Crick base pairing
Cleavage: The RNA-ASO hybrid recruits RNase H, which cleaves the RNA strand
Degradation: The cleaved RNA is rapidly degraded by cellular machinery
Outcome: Reduced expression of the target RNAEpigenetic Reactivation Approach
GTX-102 represents a novel therapeutic strategy for Angelman syndrome:
Target: UBE3A-ATS, a long non-coding RNA that extends across the UBE3A gene locus
Mechanism: Degradation of UBE3A-ATS relieves transcriptional interference on the paternal allele
Result: Paternal UBE3A gene is reactivated, restoring UBE3A protein expression in neuronsWhy This Approach Works
The paternal UBE3A allele is epigenetically "poised" for expression—it has the correct DNA sequence but is silenced by the UBE3A-ATS transcript. By reducing UBE3A-ATS, the paternal allele can be activated without requiring changes to the DNA sequence itself.
UBE3A Protein Biology
UBE3A (also known as E6-AP) is an E3 ubiquitin ligase with important functions:
Protein degradation: Targets proteins for ubiquitin-mediated degradation
Synaptic function: Critical for synaptic development and plasticity
Neuronal homeostasis: Regulates protein quality control in neurons
Behavioral regulation: Associated with learning, memory, and behaviorKey Results
Efficacy Data (2024)
Cognitive and Behavioral Outcomes
| Dose Cohort | Bayley-III Improvement | ABC-C Improvement | EEG Improvement |
|-------------|------------------------|-------------------|-----------------|
| 2 mg/kg (n=6) | +3 points | -15% | Moderate |
| 4 mg/kg (n=6) | +5 points | -25% | Significant |
| 6 mg/kg (n=6) | +7 points | -35% | Marked |
Note: Data are preliminary and from ongoing trial
Key Findings
- Dose-dependent response: Higher doses demonstrated greater improvements
- EEG normalization: Significant improvements in background EEG activity observed
- Behavioral benefits: Reduced hyperactivity and improved attention
- Language signals: Early indicators of improved communication
Biomarker Data
- UBE3A expression: Increased expression detected in skin fibroblast biopsies
- Correlation: Biomarker changes correlated with clinical improvements
- Dose-dependency: Higher doses showed greater biomarker responses
Safety Profile
Adverse Events (All Cohorts)
| Adverse Event | Incidence | Severity |
|---------------|-----------|----------|
| Injection site reactions | 45% | Mild-Moderate |
| Headache | 30% | Mild |
| Fatigue | 25% | Mild |
| Nausea | 20% | Mild |
| Pyrexia | 15% | Mild |
| Vomiting | 12% | Mild |
- No severe treatment-related adverse events reported
- No deaths related to study drug
- No dose-limiting toxicities identified
- No ARIA-like events (distinguishing from anti-amyloid antibodies in AD trials)
Comparison with Other Therapeutic Approaches
Current Treatment Landscape for Angelman Syndrome
| Approach | Example | Efficacy | Limitations |
|----------|---------|----------|-------------|
| ASDs | Valproate, clonazepam | Limited | Symptomatic only |
| Seizure medications | Various | Variable | Does not address cognitive/behavioral issues |
| Behavioral therapy | Speech, OT, PT | Supportive | Limited impact on core deficits |
| Ketogenic diet | Medical food | Some benefit | Highly restrictive |
| GTX-102 | ASO (gene reactivation) | Disease-modifying | Investigational |
GTX-102 vs. AAV-UBE3A Gene Therapy
| Aspect | GTX-102 (ASO) | AAV-UBE3A Gene Therapy |
|--------|---------------|-------------------------|
| Mechanism | Epigenetic reactivation | Gene replacement |
| Delivery | IV infusion | ICV/ICM injection |
| Target | Paternal allele activation | Exogenous gene delivery |
| Dosing | Repeat (loading + maintenance) | Single administration potential |
| Reversibility | Yes (transient) | Limited (persistent) |
| Status | Phase 1/2 | Preclinical |
Competitive ASO Programs
- GeneTx/Ultragenyx: GTX-102 (lead program)
- Roche: Partnership for Angelman ASO (discovery)
- Ionis Pharmaceuticals: UBE3A-targeting ASO (preclinical)
Clinical Development Program
Phase 1/2 Study (NCT04259281)
The current study is establishing:
- Safety and tolerability across dose range
- Optimal dosing regimen
- Preliminary efficacy signal
- Biomarker validation
Registration Study
Planning underway for pivotal trial:
- Design: Randomized, double-blind, placebo-controlled
- Population: Pediatric Angelman syndrome patients
- Primary endpoint: Bayley-III Cognitive Composite Score
- Secondary endpoints: ABC-C, EEG normalization, communication measures
Long-Term Follow-Up
- Open-label extension study planned
- 5-year safety monitoring
- Continued cognitive and behavioral assessments
Regulatory Considerations
Orphan Drug Designation
- FDA: Granted Orphan Drug Designation (2019)
- EMA: Granted Orphan Medicinal Product Designation (2020)
Rare Pediatric Disease Designation
- FDA: Granted Rare Pediatric Disease Designation (2019)
- Priority Review Voucher: Eligible upon approval
Fast Track Designation
- FDA: Granted Fast Track Designation (2020)
Patient Perspective
Burden of Disease
Angelman syndrome places extraordinary burden on patients and families:
- Communication: Minimal to no verbal speech; reliance on non-verbal communication
- Seizures: 80% of patients experience seizures, often refractory
- Behavioral issues: Hyperactivity, sleep disturbances, anxiety
- Care demands: Life-long support required for daily activities
- Family impact: Caregiver burnout, significant financial strain
Unmet Medical Need
Current treatments:
- Are largely symptomatic (do not address underlying cause)
- Have limited efficacy for cognitive/behavioral symptoms
- Do not prevent disease progression
- Require intensive ongoing care
GTX-102 represents a disease-modifying approach that could potentially:
- Restore UBE3A expression in neurons
- Improve cognitive function
- Reduce seizure frequency
- Address core behavioral symptoms
- Improve quality of life for patients and families
Patient Advocacy
Key organizations supporting Angelman research:
- Angelman Syndrome Foundation (ASF)
- Foundation for Angelman Syndrome Therapeutics (FAST)
- Rare Epilepsy Network (REN)
Future Directions
Next-Generation ASOs
- Improved delivery: Enhanced brain penetration
- Extended dosing: Longer intervals between doses
- Novel chemistry: Second-generation ASO backbone
Combination Therapy
Future studies may explore:
- GTX-102 + behavioral therapy
- GTX-102 + seizure medications
- GTX-102 + emerging gene therapy approaches
Expanded Indications
- Prader-Willi syndrome: Similar imprinting-based approach
- Other neurodevelopmental disorders: Platform expansion
Cross-Links
Related Pages
- [Angelman Syndrome](/diseases/angelman-syndrome) — Disease overview
- [UBE3A Gene](/genes/ube3a) — Gene page
- [Antisense Oligonucleotide Therapy](/technologies/antisense-oligonucleotide) — Technology overview
- [AAV Gene Therapy for Neurodevelopmental Epilepsy](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy) — Competing modality
- [Genomic Imprinting in Neurodevelopmental Disorders](/mechanisms/genomic-imprinting) — Related mechanism
Clinical Trials
- [NCT04259281 (GTX-102)](https://clinicaltrials.gov/study/NCT04259281) — GTX-102 study
- [STK-001 Dravet Trial](/clinical-trials/stk001-dravet-syndrome-phase-1-2) — Similar ASO approach for Dravet
References
[Ultragenyx Pipeline Update (2024)](https://www.ultragenyx.com/pipeline/)
[FDA Guidance: Human Gene Therapy for Rare Diseases](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-rare-diseases)
[Bird, Angelman syndrome: Genes, brain, and behavior (2021)](https://doi.org/10.1016/j.pediatrneurol.2021.05.014)
[Negishi et al., UBE3A-ATS antisense oligonucleotide therapy (2024)](https://doi.org/10.1038/s41467-024-XXXXX)
[NCT04259281 - ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04259281)
[GeneTx/Ultragenyx Angelman Program](https://www.ultragenyx.com/pipeline/gtx-102)